NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen, Inc (NASDAQ:AXGN) issued its quarterly earnings data on Monday, February, 24th. The medical equipment provider reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. The medical equipment provider had revenue of $28.16 million for the quarter, compared to analysts' expectations of $28.10 million. AxoGen had a negative net margin of 27.30% and a negative return on equity of 19.32%. AxoGen's revenue was up 20.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.09) EPS. View AxoGen's Earnings History.

AxoGen is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for AxoGen.

AxoGen issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $124-128 million, compared to the consensus revenue estimate of $131.75 million.

5 Wall Street analysts have issued 1-year price objectives for AxoGen's stock. Their forecasts range from $21.00 to $28.00. On average, they expect AxoGen's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 89.8% from the stock's current price. View Analyst Price Targets for AxoGen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

Media headlines about AXGN stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AxoGen earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for AxoGen.

AxoGen saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,660,000 shares, a decrease of 18.6% from the January 15th total of 2,040,000 shares. Based on an average daily volume of 355,000 shares, the days-to-cover ratio is presently 4.7 days. Currently, 4.7% of the shares of the stock are sold short. View AxoGen's Current Options Chain.

Some companies that are related to AxoGen include InMode (INMD), Natus Medical (NTUS), Zynex (ZYXI), TransMedics Group (TMDX), Cutera (CUTR), Semler Scientific (SMLR), Viewray (VRAY), BioLife Solutions (BLFS), Stereotaxis (STXS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Exelixis (EXEL), Advanced Micro Devices (AMD), Xilinx (XLNX), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Micron Technology (MU), Amarin (AMRN) and NVIDIA (NVDA).

AxoGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (15.15%), Baillie Gifford & Co. (2.61%), State Street Corp (2.55%), William Blair Investment Management LLC (2.34%), Bank of New York Mellon Corp (2.22%) and Bank of America Corp DE (2.21%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

AXGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Renaissance Technologies LLC, Peregrine Capital Management LLC, Goldman Sachs Group Inc., Penn Capital Management Co. Inc., Perkins Capital Management Inc. and BerganKDV Wealth Management LLC. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

AXGN stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Point72 Asset Management L.P., Bank of America Corp DE, Bank of Montreal Can, Jacobs Levy Equity Management Inc., Granite Investment Partners LLC and Baillie Gifford & Co.. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXGN stock can currently be purchased for approximately $12.12.

AxoGen has a market capitalization of $478.38 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. View Additional Information About AxoGen.

The official website for AxoGen is http://www.axogeninc.com/.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]